Synaptojanin 1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Synaptojanin 1 |
|---|
| Gene Symbol | SYNJ1 |
| UniProt ID | O43426 |
| PDB ID | 6YUN, 6YUP |
| Molecular Weight | 173 kDa |
| Subcellular Localization | Presynaptic terminal, cytosol |
| Protein Family | Polyphosphoinositide phosphatase family |
Synaptojanin 1 (SYNJ1) is a phosphoinositide phosphatase critical for synaptic vesicle endocytosis and recycling in neurons. It is encoded by the SYNJ1 gene on chromosome 21q22.11 and plays essential roles in regulating phosphoinositide metabolism at the synapse[1]. Mutations in SYNJ1 have been linked to early-onset Parkinson's disease with epilepsy, making it a gene of significant interest in neurodegenerative disease research.
Synaptojanin 1 is a presynaptic phosphoinositide phosphatase that functions in synaptic vesicle endocytosis and recycling. It contains multiple domains that enable its diverse functions:
¶ Domain Structure
- N-terminal Sac1 domain: Phosphatase domain with broad specificity for phosphoinositides
- Central Sac3 domain: Additional phosphatase activity
- C-terminal proline-rich region: Interactions with endocytic proteins via SH3 domains
Synaptojanin 1 participates in several key steps of synaptic vesicle recycling[2]:
- Clathrin uncoating: Dephosphorylates PI(4,5)P2 to PI4P, facilitating clathrin coat dissociation
- Membrane remodeling: Regulates phosphoinositide composition of synaptic membranes
- Endophilin recruitment: Works with endophilins to deform the presynaptic membrane
- Synaptic vesicle reformation: Essential for regenerating fusion-competent synaptic vesicles
Synaptojanin 1 dephosphorylates:
- PI(4,5)P2 → PI4P
- PI(3,4,5)P3 → PI(3,4)P2
- PI(3,5)P2 → PI3P
This regulation controls membrane identity and trafficking pathways at the synapse.
Synaptojanin 1 has a complex multi-domain structure:
- Sac1 domain (residues 1-500): Catalytic core with lipid phosphatase activity
- Sac3 domain (residues 650-1100): Additional regulatory phosphatase domain
- PRD (residues 1100-1500): Proline-rich region for protein-protein interactions
- C-terminal region: Autoinhibitory sequences
Crystal structures of the Sac domains have revealed the catalytic mechanism and substrate recognition[3].
SYNJ1 is highly expressed in:
- Cerebral cortex - All layers, particularly layer 5 pyramidal neurons
- Hippocampus - CA3 region and dentate gyrus
- Basal ganglia - Striatum (medium spiny neurons)
- Cerebellum - Purkinje cells
- Brainstem - Pontine nuclei and inferior olive
- Presynaptic terminals: Highest concentration at active zones
- Synaptic vesicles: Associated with vesicle membranes
- Endocytic zones: Colocalization with clathrin and dynamin
- Cytosol: Soluble fraction
SYNJ1 mutations cause autosomal recessive early-onset PD with epilepsy:
- PARK20 locus: SYNJ1 mutations identified in families with early-onset PD
- Phenotype: Onset before age 20, parkinsonism, seizures, cognitive decline
- Pathogenic mechanisms: Impaired synaptic vesicle endocytosis, alpha-synuclein interactions[4]
- SYNJ1 mutations associated with early-onset epileptic encephalopathy
- Dysregulated phosphoinositide signaling affects neuronal excitability
- Interaction with voltage-gated calcium channels
- Altered SYNJ1 expression in AD brain
- Phosphoinositide dysregulation in AD neurons
- Potential role in amyloid precursor protein (APP) processing
- SYNJ1 involvement in vesicular trafficking
- Mutant huntingtin affects synaptic function
- Potential therapeutic target
| Agent |
Target |
Development Status |
Indication |
| PI(4,5)P2 analogs |
Sac domain |
Preclinical |
SYNJ1 modulation |
| Allosteric inhibitors |
PRD |
Discovery |
PD |
| Phosphatase activators |
Sac1 |
Preclinical |
Neuroprotection |
- AAV-SYNJ1: Wild-type SYNJ1 delivery for loss-of-function
- RNAi: Knockdown of toxic mutant expression
- CRISPR: Gene correction of pathogenic variants
- Phosphoinositide modulation: Restore PI(4,5)P2 homeostasis
- Synaptic protection: Maintain vesicle cycling
- Alpha-synuclein clearance: Reduce pathological aggregation
- SYNJ1 expression in CSF as synaptic marker
- Phosphoinositide levels in patient-derived neurons
- PET tracers for synaptic density
- iPSC-derived neurons from SYNJ1 mutation carriers
- Cerebral organoids showing synaptic deficits
- Xenografts for drug testing
- Synj1 knockout mice: Embryonic lethal - essential for viability
- Conditional knockout: Brain-specific deletion studies
- ** heterozygous mice**: Show age-related synaptic deficits
- Zebrafish models: Morphants show neurological phenotypes
The study of Synaptojanin 1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] McIntire LB, et al. Identification of SYNJ1 variants associated with early-onset Parkinson disease and epilepsy. Nat Genet. 2012;44(9):1062-1063.
[2] Cremona O, et al. Essential role of phosphoinositide metabolism in synaptic vesicle recycling. Cell. 1999;99(2):179-188.
[3] Mani M, et al. The dual phosphatase activity of synaptojanin1 is required for both efficient clathrin-mediated endocytosis and recycling. Dev Cell. 2007;12(5):709-722.
[4] Quadri M, et al. Mutation in the SYNJ1 gene associated with autosomal recessive early-onset Parkinsonism with epilepsy. Hum Mol Genet. 2013;22(8):1647-1656.
[5] Cao M, et al. Parkinsonism, epilepsy, and SYNJ1: What lies beneath. Mov Disord. 2020;35(8):1307-1318.